Malignant pleural mesothelioma is an asbestos-related neoplasm with poor prognosis, refractory to current therapies, the incidence of which is expected to increase.
The stages identify tumours that have a similar prognosis and thus are treated in a similar way. Patients with lower stage numbers tend to have a better prognosis. Stage I. T1, N0, M0: Mesothelioma involves either the right or left pleura lining the chest wall or diaphragm.
Mesothelioma is a type of cancer that typically occurs due to exposure to asbestos. A mesothelioma prognosis depends on the stage of the disease and the age of the patient. Of the four types of mesothelioma, pleural malignant mesothelioma is the most common.
A malignant (cancerous) tumour of the mesothelium is called a malignant mesothelioma. As most mesothelial tumours are cancerous, malignant mesothelioma is often simply called mesothelioma. This type has the best prognosis (outlook for survival). The other two types are the sarcomatoid type (7%-20%), and the mixed/biphasic type (20%-35%). Malignant pleural mesothelioma (MPM) is a disease with a very dismal prognosis. A median survival of 6-18 months is expected in most patients.
Friday, 6 November 2009
Wednesday, 4 November 2009
In 2006, the five-year survival rate for mesothelioma was estimated at around 10 percent.
In 2006, the five-year survival rate for mesothelioma was estimated at around 10 percent. Typically the most important variable determining the prognosis and life expectancy of a mesothelioma patient is the stage of the cancer when it is diagnosed. Since mesothelioma is usually diagnosed at an advanced stage, the statistics for five year survival for early stage mesothelioma are usually unreliable.
Cell type plays a role in a mesothelioma prognosis analysis. The two types of cells that develop into mesothelioma cancers are epithelioid cells and sarcomatoid cells. Prognosis Factors. One of the critical issues with a mesothelioma diagnosis is the question of whether or not the disease has been caught early enough that surgery is an option. Most mesothelioma diagnoses don't meet this standard. Because its symptoms are vague and its onset can be slow, mesothelioma carries a poor prognosis, with a median survival time of only 6 to 18 months. Diffuse malignant peritoneal mesothelioma (DMPM), the more rare type that begins in the abdomen, has overall survival rates averaging one year.
Cell type plays a role in a mesothelioma prognosis analysis. The two types of cells that develop into mesothelioma cancers are epithelioid cells and sarcomatoid cells. Prognosis Factors. One of the critical issues with a mesothelioma diagnosis is the question of whether or not the disease has been caught early enough that surgery is an option. Most mesothelioma diagnoses don't meet this standard. Because its symptoms are vague and its onset can be slow, mesothelioma carries a poor prognosis, with a median survival time of only 6 to 18 months. Diffuse malignant peritoneal mesothelioma (DMPM), the more rare type that begins in the abdomen, has overall survival rates averaging one year.
Monday, 2 November 2009
An asbestosis prognosis can be determined following diagnosis of the asbestos lung cancer
Cisplatin treatment is often used for malignant mesothelioma patients who are not good candidates for surgery. Malignant mesothelioma usually is advanced by the time it is diagnosed, so the outlook usually is poor. On average, the survival time after diagnosis is about one year.
Prognosis and prognostic factors of malignant Pleuramesothelioms Overall, the prognosis of patients at a Pleuramesotheliom malignant disease, with and without therapy is bad. The median survival time is about 7-10 months from time of diagnosis.
An asbestosis prognosis can be determined following diagnosis of the asbestos lung cancer. While asbestosis itself is non-malignant and not directly fatal, its effects can be associated with eliciting secondary conditions that can result in death. Pleural mesothelioma is a difficult cancer to treat because it can spread so extensively and it is generally not diagnosed early enough. Pleural mesothelioma patients have a poorer prognosis if they are experiencing chest pain, shortness of breath, inability to perform daily tasks, or weight loss.
Prognosis and prognostic factors of malignant Pleuramesothelioms Overall, the prognosis of patients at a Pleuramesotheliom malignant disease, with and without therapy is bad. The median survival time is about 7-10 months from time of diagnosis.
An asbestosis prognosis can be determined following diagnosis of the asbestos lung cancer. While asbestosis itself is non-malignant and not directly fatal, its effects can be associated with eliciting secondary conditions that can result in death. Pleural mesothelioma is a difficult cancer to treat because it can spread so extensively and it is generally not diagnosed early enough. Pleural mesothelioma patients have a poorer prognosis if they are experiencing chest pain, shortness of breath, inability to perform daily tasks, or weight loss.
Subscribe to:
Comments (Atom)
